CoChat
Sign Up
Cited by 65

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

The status of hematopoietic stem cell transplantation in lysosomal storage disease

Malatack, J.Jeffrey, Consolini, Deborah M, Bayever, Eliel·2003·Pediatric Neurology
DOI 10.1016/j.pediatrneurol.2003.09.003
Open this paper in CoChat — free account

Abstract

Lysosomal storage diseases are a group of disorders which have in common an inherited defect in lysosomal function-in most cases, a missing intralysosomal enzyme. Research into potential treatment options for this group of disorders has focused on enzyme replacement. Over the past two decades, hematopoietic stem cell transplantation has been used with increasing frequency to treat patients with lysosomal storage disease by providing a population of cells with the capacity to produce the missing enzyme. The success of marrow transplantation depends on the specific enzyme deficiency and the stage of the disease. Generally, visceral symptoms can be improved, whereas skeletal lesions remain relatively unaffected. The effect on neurologic symptoms varies. Hematopoietic stem cell transplantation remains a viable treatment option in those lysosomal storage diseases where data supportive of disease stabilization or amelioration are known. Early transplantation is the goal so that enzyme replacement may occur before extensive central nervous system injury becomes evident. When inadequate clinical data are available, the decision to perform transplantation requires experimental data demonstrating that the enzyme in question is both excreted from normal cells and taken up by affected cells as evidenced by elimination of storage material in vitro.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.pediatrneurol.2003.09.003

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 2 references

Research works printed but not linked: 50

  1. Masek, 1999, Quality of life assessment in adults with Type 1 Gaucher disease, Quality of Life Res, 8, 263, 10.1023/A:1008859420641 · DOI
  2. Eng, 2001, International Collaborative Fabry Disease Study Group. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry disease, N Engl J Med, 345, 9, 10.1056/NEJM200107053450102 · DOI
  3. van den Hout, 2000, Recombinant human alpha-glucosidase from rabbit milk in Pompe patients, Lancet, 358, 397, 10.1016/S0140-6736(00)02533-2 · DOI
  4. Neufeld EF. Replacement of genotype specific proteins in mucopolysaccharidosis enzyme therapy in genetic disease. In: Desnick RJ, Bernlohr RW, Krivit W, eds. Birth defects March of Dimes original series IX. Baltimore, MD: Williams & Wilkins, 1973;2:27-30
  5. Hobbs, 1981, Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation, Lancet, 2, 709, 10.1016/S0140-6736(81)91046-1 · DOI
  6. Krivit, 1992, Maroteaux-Lamy Syndrome (Mucopolysaccharidosis Type VI), Int Pediatr, 7, 47
  7. Bayever, 1985, Bone marrow transplantation for metachromatic leukodystrophy, Lancet, 31, 471, 10.1016/S0140-6736(85)90402-7 · DOI
  8. Krivit, 2002, Stem cell bone marrow transplantation in patients with metabolic storage diseases, Advances in Pediatrics, 49, 359
  9. O'Brien, 1973, Sanfilippo disease type B, Science, 181, 753, 10.1126/science.181.4101.753 · DOI
  10. Yeager, 1984, Prolonged survival and remyelination after hematopoietic cell transplantation in the twitcher mouse, Science, 225, 1052, 10.1126/science.6382609 · DOI
  11. Hoogerbrugge, 1988, Donor-derived cells in the CNS of twitcher mice after bone marrow transplantation, Science, 239, 1035, 10.1126/science.3278379 · DOI
  12. Hoogerbrugge, 1995, (for the European group for bone marrow transplantation). Allogeneic bone marrow transplantation for lysosomal storage disease, Lancet, 345, 1398, 10.1016/S0140-6736(95)92597-X · DOI
  13. Parkman, 1996, Bone marrow transplantation for metabolic diseases, Immunol Allergy Clin North Am, 16, 429, 10.1016/S0889-8561(05)70254-X · DOI
  14. Shapiro, 1995, Neurophysiological outcomes of several storage diseases with and without bone marrow transplantation, J Inher Metab Dis, 18, 413, 10.1007/BF00710053 · DOI
  15. Kato, 1986, Bone marrow transplantation in children, Tokai J Exp Clin Med, 11, S43
  16. Wraith, 2001, Advances in the treatment of lysosomal storage diseases, Dev Med Child Neuro, 43, 639, 10.1017/S0012162201001165 · DOI
  17. Krivit, 1995, The future for treatment by bone marrow transplantation for adrenoleukodystrophy, metachromatic leukodystrophy, globoid cell leukodystrophy and Hurler syndrome, J Inher Metab Dis, 18, 398, 10.1007/BF00710052 · DOI
  18. Hoogerbrugge, 1998, Bone marrow transplantation and gene therapy for lysosomal storage diseases, Bone Marrow Transplantation, 21, S34
  19. Guiffon, 1998, Follow up of nine patients with Hurler syndrome after bone marrow transplantation, J Pediatrics, 133, 119, 10.1016/S0022-3476(98)70201-X · DOI
  20. Peters, 1998, Hurler syndrome, Blood, 91, 2601, 10.1182/blood.V91.7.2601 · DOI
  21. McKinnis, 1996, Bone marrow transplantation in Hunter syndrome, J Pediatrics, 129, 145, 10.1016/S0022-3476(96)70202-0 · DOI
  22. Peters, 2000, Hematopoietic cell transplantation for mucopolysaccharidosis IIB (Hunter syndrome), Bone Marrow Transplantation, 25, 1097, 10.1038/sj.bmt.1702398 · DOI
  23. Herskhovitz, 1999, Bone marrow transplantation for Maroteaux-Lamy syndrome (MPS VI), J Inher Metab Dis, 22, 50, 10.1023/A:1005447232027 · DOI
  24. Ponder, 2002, Therapeutic neonatal hepatic gene therapy in mucopolysaccharidosis VII dogs, Proc Natl Acad Sci USA, 99, 13102, 10.1073/pnas.192353499 · DOI
  25. Kurobane, 1986, Biochemical improvement after treatment by bone marrow transplantation in I-cell disease, Tohoku J Exp Med, 150, 63, 10.1620/tjem.150.63 · DOI
  26. Imaizumi, 1994, Long-term effects of bone marrow transplantation for inborn errors of metabolism, Acta Paediatrica Japonica, 36, 30, 10.1111/j.1442-200X.1994.tb03125.x · DOI
  27. Platt, 1998, New therapeutic prospects for the glycosphingolipid lysosomal storage diseases, Biochem Pharmacol, 56, 421
  28. Krivit, 1998, Hematopoietic stem-cell transplantation in globoid-cell leukodystrophy, N Engl J Med, 338, 1119, 10.1056/NEJM199804163381605 · DOI
  29. Krivit, 1999, Bone marrow transplantation for globoid cell leukodystrophy, adrenoleukodystrophy, metachromatic leukodystrophy, and Hurler syndrome, Curr Opin Hematol, 6, 337, 10.1097/00062752-199911000-00004 · DOI
  30. Schiffmann, 2002, New prospects for the treatment of lysosomal storage diseases, Drugs, 62, 733, 10.2165/00003495-200262050-00002 · DOI
  31. Pastores, 2002, Advances in the management of Anderson-Fabry disease, Expert Opin Biol Therapy, 2, 325, 10.1517/14712598.2.3.325 · DOI
  32. Yeager, 2000, Bone marrow transplantation for infantile ceramidase deficiency (Farber disease), Bone Marrow Transplantation, 26, 357, 10.1038/sj.bmt.1702489 · DOI
  33. Morales, 1996, Gaucher's disease, Ann Pharmacother, 30, 381, 10.1177/106002809603000411 · DOI
  34. Bayever, 1992, Bone marrow transplantation for Niemann-Pick type IA disease, J Inher Metab Dis, 15, 919, 10.1007/BF01800234 · DOI
  35. Vellodi, 1987, Treatment of Niemann-Pick disease type B by allogeneic bone marrow transplantation, BMJ Clin Res Ed, 295, 1375, 10.1136/bmj.295.6610.1375 · DOI
  36. Wall, 1998, Bone marrow transplantation for the treatment of alpha-mannosidosis, J Pediatrics, 133, 282, 10.1016/S0022-3476(98)70237-9 · DOI
  37. Walkley, 1994, Bone marrow transplantation corrects the enzyme defect in neurons of the central nervous system in lysosomal storage disease, Proc Natl Acad Sci USA, 91, 2970, 10.1073/pnas.91.8.2970 · DOI
  38. Will, 1987, Bone marrow transplantation in the treatment of alpha-mannosidosis, Arch Dis Child, 62, 1044, 10.1136/adc.62.10.1044 · DOI
  39. Taylor, 1992, Amelioration of clinical disease following bone marrow transplantation in fucosidase-deficient dogs, Am J Med Gen, 42, 628, 10.1002/ajmg.1320420439 · DOI
  40. Vellodi, 1995, Allogeneic bone marrow transplantation for fucosidosis, Bone Marrow Transplantation, 15, 153
  41. Miano, 2001, Four year follow-up of a case of fucosidosis treated with unrelated donor bone marrow transplantation, Bone Marrow Transplantation, 27, 747, 10.1038/sj.bmt.1702994 · DOI
  42. Arvio, 2001, Bone marrow transplantation for aspartylglucosaminuria, J Pediatrics, 138, 288, 10.1067/mpd.2001.110119 · DOI
  43. Amalfitano, 2001, Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II, Genet Med, 3, 132
  44. Hsu, 1999, Niemann-Pick disease type C (a cellular cholesterol lipidosis) treated by bone marrow transplantation, Bone Marrow Transplantation, 24, 103, 10.1038/sj.bmt.1701826 · DOI
  45. Krivit, 1992, Wolman's disease, Bone Marrow Transplantation, 10, S97
  46. Krivit, 2000, Wolman disease successfully treated by bone marrow transplantation, Bone Marrow Transplantation, 26, 567, 10.1038/sj.bmt.1702557 · DOI
  47. Deeg, 1990, Batten's disease, Clin Genet, 37, 264, 10.1111/j.1399-0004.1990.tb04188.x · DOI
  48. Lake, 1995, Bone marrow transplantation in Batten disease (neuronal ceroid-lipofuscinosis). Will it work? Preliminary studies on coculture experiments and on bone marrow transplant in late infantile Batten disease, Am J Med Gen, 57, 369, 10.1002/ajmg.1320570253 · DOI
  49. Hahn, 1998, Correction of murine galactosialidosis by bone marrow-derived macrophages overexpressing human protective protein/cathepsin A under control of the colony-stimulating factor-1 receptor promoter, Proc Natl Acad Sci USA, 95, 14880, 10.1073/pnas.95.25.14880 · DOI · Paper page
  50. Leimig, 2002, Functional amelioration of murine galactosialidosis by genetically modified bone marrow hematopoietic progenitor cells, Blood, 99, 3169, 10.1182/blood.V99.9.3169 · DOI · Paper page

Cited by

See all 65

Metadata

Authors
Malatack, J. J., Consolini, D. M., & Bayever, E.
Venue
Pediatric Neurology
Publisher
Elsevier BV
Published
2003-11
Volume
29
Issue
5
Pages
391-403
ISSN
0887-8994
DOI
10.1016/j.pediatrneurol.2003.09.003
Cited by
65
References
2
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The status of hematopoietic stem cell transplantation in lysosomal storage disease. https://app.cochat.ai/papers/10.1016/j.pediatrneurol.2003.09.003
The paper
Malatack, J. J., Consolini, D. M., & Bayever, E. (2003). The status of hematopoietic stem cell transplantation in lysosomal storage disease. Pediatric Neurology. https://doi.org/10.1016/j.pediatrneurol.2003.09.003